Beyond exhaustion: T cell fitness for next generation of immunotherapy for hematological cancer.

Authors

Xiaoshuang Kong, Yuanhui Su, Hanxue Zheng, Zuxi Feng, Jianxia Huang, Liansheng Zhang, Lijuan Li

Published in

Frontiers in immunology. Volume 17. Pages 1895434. Epub Jul 27, 2026.

Abstract

T cell-directed immunotherapies have transformed the treatment of hematological malignancies, but durable benefit remains limited by relapse, poor persistence, incomplete immune reconstitution and infection. These outcomes depend not only on target-antigen expression but also on the functional quality of the T cell compartment. In this Review, we define T cell fitness as a multidimensional capacity that includes cellular availability, memory reserve, proliferative competence, cytotoxic function, metabolic resilience, resistance to chronic stimulation and persistence. We distinguish exhaustion, senescence and terminal differentiation as overlapping but non-equivalent states and propose a measurable, modality-specific assessment framework rather than reliance on a single marker. We then compare how these states arise in multiple myeloma, lymphoma, acute lymphoblastic leukemia and acute myeloid leukemia, emphasizing the effects of age, tissue niche, disease burden and prior therapy. We critically appraise evidence from CAR-T cell therapy, bispecific antibodies and checkpoint blockade, including the limitations of predominantly retrospective, correlative and disease-specific datasets. Finally, we translate the fitness framework into clinical questions: when to collect cells, how to select bridging therapy, which biomarkers merit prospective testing, how treatment duration and sequencing may preserve immune competence, and where gene-edited products, CAR-NK cells and metabolic interventions may reduce dependence on compromised autologous T cells. A fitness-based approach may support more precise biomarker development and safer treatment selection, but prospective validation and modality-specific thresholds are still required.

PMID:
42577301
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.